1. Home
  2. GLPG vs CENTA Comparison

GLPG vs CENTA Comparison

Compare GLPG & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.75

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Central Garden & Pet Company Nonvoting

CENTA

Central Garden & Pet Company Nonvoting

HOLD

Current Price

$34.27

Market Cap

2.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
CENTA
Founded
1999
1955
Country
Belgium
United States
Employees
452
6000
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GLPG
CENTA
Price
$27.75
$34.27
Analyst Decision
Buy
Hold
Analyst Count
2
4
Target Price
$36.50
$36.75
AVG Volume (30 Days)
129.6K
256.2K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.60
Revenue Next Year
N/A
$2.04
P/E Ratio
N/A
$13.52
Revenue Growth
N/A
N/A
52 Week Low
$25.97
$25.97
52 Week High
$37.78
$37.71

Technical Indicators

Market Signals
Indicator
GLPG
CENTA
Relative Strength Index (RSI) 36.53 55.02
Support Level N/A $30.85
Resistance Level $34.04 $35.30
Average True Range (ATR) 0.56 1.22
MACD 0.08 0.01
Stochastic Oscillator 25.33 40.76

Price Performance

Historical Comparison
GLPG
CENTA

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About CENTA Central Garden & Pet Company Nonvoting

Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.

Share on Social Networks: